Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COGNITION THERAPEUTICS INCCGTX · Entity 6792 | Chief Financial Officer | May 01, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COGNITION THERAPEUTICS INC
Report date May 01, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 618,942 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Tax withholding · Disposed 8,567 · Balance 618,942 F1: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHIASMA, INC
Report date August 05, 2021 · Filed August 05, 2021
Section 16 reporting ended · disclosed 2021-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2021-08-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-05 · Disposition to issuer · Disposed 175,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").
F2: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 4, 2026 20:01 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | Tax withholdingCommon Stock | 8,567 | $1.28 | $10,965.76 |
DisclosureSEC source: 0001104659-26-054858 · tm2613475-1_4seq1.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,942 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 20:18 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | PurchaseCommon Stock | 10,000 | $1.13 | $11,300.00 |
DisclosureSEC source: 0001104659-26-045511 · tm2612247-3_4seq1.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,509 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:16 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | Tax withholdingCommon Stock | 1,560 | $1.12 | $1,747.20 |
DisclosureSEC source: 0001104659-26-017068 · tm266602-2_4seq1.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 617,509 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 22:27 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | Tax withholdingCommon Stock | 26,921 | $1.03 | $27,728.63 |
DisclosureSEC source: 0001104659-26-011074 · tm265419-2_4seq1.xml · nonDerivative · entry 2 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 619,069 F2 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 22:27 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011074 · tm265419-2_4seq1.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645,990 F1 · kind: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| December 18, 2025 Filed Dec 22, 2025 21:10 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | Tax withholdingCommon Stock | 9,360 | $1.50 | $14,040.00 |
DisclosureSEC source: 0001104659-25-123721 · tm2534021-1_4seq1.xml · nonDerivative · entry 2 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,990 F2 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of PSUs. Read SEC document |
| December 18, 2025 Filed Dec 22, 2025 21:10 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-123721 · tm2534021-1_4seq1.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 455,350 F1 · kind: Shares earned upon the vesting of performance stock units ("PSUs") granted to the Reporting Person on February 14, 2024. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. The remaining 50% of the total number of shares subject to the PSUs vested on December 18, 2025. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:23 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | Tax withholdingCommon Stock | 9,360 | $0.67 | $6,273.07 |
DisclosureSEC source: 0001062993-25-013357 · form4.xml · nonDerivative · entry 2 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,350 F2 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of PSUs. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:23 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-013357 · form4.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,710 F1 · kind: Shares earned upon the vesting of performance stock units ("PSUs") granted to the Reporting Person on February 14, 2024. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. 50% of the total number of shares subject to the PSUs vested on July 29, 2025. Read SEC document |
| May 01, 2025 Filed May 2, 2025 21:53 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | Tax withholdingCommon Stock | 9,692 | $0.45 | $4,334.26 |
DisclosureSEC source: 0001062993-25-008394 · form4.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,710 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 21:28 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | Tax withholdingCommon Stock | 1,723 | $0.59 | $1,016.74 |
DisclosureSEC source: 0001062993-25-002703 · form4.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,402 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 04, 2025 Filed Feb 4, 2025 21:12 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | GrantCommon Stock | 295,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001620 · form4.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,125 F1 · kind: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:07 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | Tax withholdingCommon Stock | 8,699 | $1.95 | $16,963.05 |
DisclosureSEC source: 0001062993-24-009329 · form4.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,125 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:13 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001062993-24-003651 · form4.xml · derivative · entry 2 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-02-15 F2 · derivative.exercise_date: The option vests 25% on February 15, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:13 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003651 · form4.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,824 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:20 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | GrantStock Option (right to buy) · Derivative | 109,824 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001062993-23-010091 · form4.xml · derivative · entry 2 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,824 Underlying: Common Stock · 109,824 shares Expires 2033-05-01 F2 · derivative.exercise_date: The option vests 25% on May 1, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:20 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | GrantCommon Stock | 109,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-010091 · form4.xml · nonDerivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,824 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| August 05, 2021 Filed Aug 5, 2021 17:26 UTC | CHIASMA, INC CHMA · Entity 136487 | Disposition to issuerStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001209191-21-050010 · doc4.xml · derivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2 · kind: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 17:33 UTC | CHIASMA, INC CHMA · Entity 136487 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001209191-21-004402 · doc4.xml · derivative · entry 1 Doyle John Brendan · CIK 0001840738 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-01-19 F1 · derivative.exercise_date: This option will vest over a four-year period as follows: 25% will vest on the first anniversary of the date of grant and the remaining 75% will vest in equal monthly installments for the following 36 months, provided continued employment with the Company on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.